Identifying gene-environment interactions is a central challenge in the quest to understand susceptibility to complex, multifactorial diseases. Developing an understanding of how inter-individual variability in inherited genetic variation alters the effects of environmental exposures will enhance our knowledge of disease mechanisms and improve our ability to predict disease and target interventions to high-risk sub-populations. Limited progress has been made identifying gene-environment interactions in the epidemiological setting using existing statistical approaches for genome-wide searches for interaction. In this paper, we describe a novel two-step approach using omics data to conduct genome-wide searches for gene-environment interactions. Using existing genome-wide SNP data from a large Bangladeshi cohort study specifically designed to assess the effect of arsenic exposure on health, we evaluated gene-arsenic interactions by first conducting genome-wide searches for SNPs that modify the effect of arsenic on molecular phenotypes (gene expression and DNA methylation features). Using this set of SNPs showing evidence of interaction with arsenic in relation to molecular phenotypes, we then tested SNP-arsenic interactions in relation to skin lesions, a hallmark characteristic of arsenic toxicity. With the emergence of additional omics data in the epidemiologic setting, our approach may have the potential to boost power for genome-wide interaction research, enabling the identification of interactions that will enhance our understanding of disease etiology and our ability to develop interventions targeted at susceptible sub-populations.
Introduction
Exposure to arsenic is a serious global public health issue. More than 200 million people worldwide, including approximately 77 million in Bangladesh and 17 million in the U.S., consume drinking water contaminated with arsenic at levels associated with adverse health effects and shortened lifespan (IARC 2004; Argos et al. 2010) . Additionally, food-derived inorganic arsenic exposure is also an emerging health concern (Gilbert-Diamond et al. 2011; Xue et al. 2010; European Food Safety Authority 2009; Potera 2007; Jackson et al. 2012) . Epidemiologic research has established arsenic exposure as a risk factor for cancers of the skin, lung, bladder, kidney, liver, and possibly prostate (IARC Working Group on the Evaluation of Carcinogenic Risks to Humans 2012). Arsenic has also been associated with increased risk of cardiovascular diseases (Abhyankar et al. 2012; Navas-Acien et al. 2005; Moon et al. 2012) , non-malignant respiratory diseases (Guha Mazumder 2007) , diabetes mellitus (Maull et al. 2012; Thayer et al. 2012; Navas-Acien et al. 2006) , and impaired cognitive function (Rodriguez-Barranco et al. 2013 ).
Skin is a major target organ of arsenic, with skin lesions a hallmark characteristic of chronic exposure and an early manifestation of arsenic toxicity (Byrd et al. 1996) . A dose-response relationship between arsenic exposure and skin lesions is well established (Yoshida et al. 2004 ). However, arsenic exposure itself fails to fully explain the presence of arsenical skin lesions in exposed populations, and inter-individual variability in susceptibility due to inherited genetic variation may play an important role in determining risk (Concha et al. 2002; Ghosh et al. 2008; Hernandez and Marcos 2008) . Variation in the 10q24.32 region (containing arsenic methyltransferase; AS3MT) is associated with arsenic metabolism efficiency (Antonelli et al. 2014) , and these variants show clear additive interaction with arsenic exposure in relation to skin lesion risk (Pierce et al. 2013) . However, other than 10q24.32, there are no other established arsenic susceptibility regions (Hernandez and Marcos 2008) .
Identifying gene-environment (G×E) interactions is a central challenge to understand susceptibility to complex, multi-factorial diseases (Ritz et al. 2017) . Inter-individual variability in the effects of environmental exposures may be influenced by inherited genetic variation (Tabrez et al. 2014) . Unfortunately, limited progress has been made identifying G×E interactions in the epidemiological setting using genome-wide searches for interaction (McAllister et al. 2017 ). In the current study, we describe novel functional approaches using existing genome-wide genotype, gene expression, and DNA methylation data from a large Bangladeshi cohort study specifically designed to assess the effect of arsenic exposure on health. We evaluate genearsenic interactions by conducting genome-wide searches for genetic variants that modify the effect of arsenic on molecular phenotypes and then test SNP-arsenic interactions in relation to skin lesion status.
Methods

Participants
The study sample consists of 5354 Bangladeshi adults with existing data on arsenic exposure (measured in urine), genome-wide SNP genotypes, and clinical phenotype data. Among these participants, 3364 are from the Health Effects of Arsenic Longitudinal Study (HEALS) and 1990 are from the Bangladesh Vitamin E and Selenium Trial (BEST). Selected characteristics of the study participants are shown in Table 1 . Additional molecular data are available for a subset of BEST participants, with array-based genome-wide gene expression data on 1800 participants and array-based epigenome-wide DNA methylation data on 400 participants. HEALS is a prospective cohort study originally consisting of 11,746 men and women from Araihazar, Bangladesh, a rural area in which the primary source of drinking water is groundwater provided by hand-pumped tube wells. A large proportion of these wells access groundwater that is naturally contaminated with elevated levels of inorganic arsenic. Participants were recruited between October 2000 and May 2002. HEALS was designed to evaluate the long-and shortterm effects of arsenic consumed in drinking water and has been described extensively elsewhere (Ahsan et al. 2006a, b) . Demographic data, lifestyle data, and urine and blood samples were collected at baseline interviews. The size of the HEALS cohort was increased in 2006-2008, with an additional 8287 participants added.
BEST is a randomized chemoprevention trial of 7000 participants from Araihazar, Matlab, and surrounding areas. All participants have skin lesions associated with arsenic exposure. The study was created to evaluate vitamin E and selenium supplementation on non-melanoma skin cancer risk 
Genotype data
DNA extraction for genotyping was carried out from the whole blood using the QIAamp 96 DNA Blood Kit (cat # 51161) from Qiagen, Valencia, USA. Concentration and quality of all extracted DNA were assessed using Nanodrop 1000. Samples were processed on Illumina HumanCytoSNP-12 v2.1 chips with 299,140 markers and read on the BeadArray Reader. Image data were processed in BeadStudio software to generate genotype calls.
Quality control was conducted as described previously for 5499 individuals typed for 299,140 SNPs (Pierce et al. 2013 (Pierce et al. , 2012 . We removed DNA samples with call rates < 97% (n = 13), gender mismatches (n = 79), as well as technical duplicates (n = 53). We removed SNPs that were poorly called (< 90%) or monomorphic (n = 38,753), and then removed SNPs with call rates < 95% (n = 1045) or HWE p values < 10 −10 (n = 634, which produces no HWE p values < 10 −7 in a subset of 1842 unrelated participants). This QC resulted in 5354 individuals with high-quality genotype data for 257,747 SNPs. The MaCH software (Li et al. 2010 ) was used to conduct genotype imputation using 1000 genomes reference haplotypes (1 KG phase3 v5, which includes South Asian populations). Only high-quality autosomal imputed SNPs (imputation r 2 > 0.5) with MAF > 0.01 were included in this analysis, yielding 8,512,165 imputed SNPs.
Gene expression data
Genome-wide mRNA expression data have been generated for a subset of 1799 BEST participants using Illumina's HumanHT-12-v4 chip (47,231 transcripts covering 31,335 genes). RNA was extracted from mononuclear cells preserved in RLT buffer, stored at − 86 °C, using Qiagen RNeasy Micro Kit (cat# 74004). Concentration and quality of extracted RNA were assessed on Nanodrop 1000. cRNA synthesis was done from 250 ng of RNA using Illumina TotalPrep 96 RNA Amplification kit.
DNA methylation data
Genome-wide DNA methylation data were generated for a subset of 400 BEST participants using Illumina's HumanMethylation450 BeadChip (485,577 CpG-sites, including consensus coding sequences, miRNA promoter regions, and disease-related and imprinted genes) (Dedeurwaerder et al. 2011) . Bisulphite conversion of genomic DNA was performed using the Zymo's EZ DNA Methylation Kit. The assay was conducted using 500 ng of bisulfite-converted DNA per sample. These data have recently been used to identify CpG sites at which DNA methylation is associated with arsenic exposure (Argos et al. 2015) .
Arsenic exposure data
Urinary total arsenic concentration is a good biomarker of aggregate ingested arsenic exposure, and captures exposure from all sources including water, food, soil, and dust (Hughes 2006) . All study participants have existing urinary total arsenic data available, measured from a spot urine sample by graphite furnace atomic absorption spectrometry, with a detection limit of 2 µg/L, in a single laboratory (Trace Metals Core Facilities Laboratory at Columbia University) (Nixon et al. 1991) . Urinary creatinine concentration has also been measured in the same laboratory by a colorimetric method based on the Jaffe reaction (Heinegard and Tiderstrom 1973) . Urinary total arsenic was divided by creatinine to obtain a creatinine-adjusted urinary total arsenic concentration, expressed as µg/g creatinine.
Analytical strategy
The general analysis approach is described in Fig. 1 . As described in detail below, we used a two-step approach in an attempt to (1) identify SNPs that modify the effect of arsenic on molecular ("omic") phenotypes (i.e., gene expression and DNA methylation phenotypes, measured genome-wide) and (2) use this set of SNPs to test SNP-arsenic interactions in relation to skin lesion status, the classical sign of arsenic toxicity.
Step 1: Identifying SNPs that interact with arsenic to influence molecular "-omic" phenotypes To identify SNPs that interact with arsenic to influence specific genome features (i.e., individual transcripts or CpGs), we first identified a set of transcripts and a set of CpG methylation sites that show strong evidence of association with arsenic exposure, based on Bonferroni (and/or FDR correction). This was done based largely on our previously reported results on this topic (Argos et al. 2015) . For each arsenic-associated feature (i.e., CpG or transcript), we then conducted a genome-wide search for SNPs that modify the association between arsenic and the selected feature. In order to identify SNPs that modify the effect of arsenic on multiple features, we conducted principal component analysis (PCA) of the arsenic-associated features, and derived arsenic-associated PCs representing the impact of arsenic on the "biological system" represented by the features. These PCs were then used as outcome variables to conduct genomewide screens for SNPs that modify the effect of arsenic on the biological system, as represented by PCs.
We also conducted genome-wide cis-eQTL (expression quantitative trait loci) and cis-meQTL (methylation QTL) analyses and examined statistical interaction between arsenic exposure and the lead cis-SNP in relation to the transcript or CpG affected by the SNP. To identify eQTLs and meQTLs, we leveraged results from our recent studies of eQTLs and meQTLs in the BEST study (Pierce et al. 2014 (Pierce et al. , 2016 . At a false-discovery rate (FDR) of 0.01, we observed 7643 ciseQTLs and 84,853 cis-meQTLs. Using the lead SNP for each observed eQTL and meQTL, we tested SNP-arsenic interaction in relation to the associated transcript or CpG.
Step 2: Identifying SNPs that interact with arsenic to influence arsenic-related disease Each SNP identified in step 1 was tested for interaction with arsenic in relation to arsenic-induced skin lesions, the most common sign of arsenic toxicity. This SNP-arsenic interaction analysis was restricted to 503 incident skin lesion cases and 2493 lesion-free controls from HEALS. For each SNP identified in step 1, we also tested the marginal association between the SNP and skin lesion status, using data on the combined HEALS and BEST studies (2493 skin lesion cases and 2861 controls).
Regression modeling approach (for both steps)
Our study participants reside in a relatively small geographic area, and some participants are related to other participants. Rather than exclude relatives, we use mixed effects models to account for relatedness. Such models have been developed for the GWA setting, including the software GEMMA. All regression analyses were conducted using the GEMMA software package (Zhou and Stephens 2012) . Regression models for detection of G×E include marginal effects for the genetic variant (coded as 0, 1, or 2 minor alleles) and for arsenic (log-transformed continuous), as well as an interaction term that is the product of these two variables. Arsenic exposure was also modeled as an ordinal and a dichotomous variable in supplementary analyses, to insure that our interactions findings are not affected by mis-modeling the effect of the exposure on the outcome. All regression models are adjusted for sex and age (continuous). For binary outcomes (step 2), a Fig. 1 Analysis approach. A two-stage "G×E-omics" approach for detecting G×E linear mixed model treating binary outcomes as continuous variables was used. To approximate the corresponding odds ratio (OR), the beta coefficient was first divided by [x(1 -x) ], where x is the proportion of cases in the analysis sample, in order to estimate the beta from a logistic model. This quantity was exponentiated to obtain an OR.
G×E analysis of SNPs that are eQTLs in skin
In addition to the two-step analyses described above, we also studied the effects of SNPs known to be eQTLs in skin on skin lesion risk. Based on eQTL results from the GTEx project (Genotype-Tissue Expression Project), we selected the lead SNP for each eQTL observed in sun-unexposed skin (suprapubic) and sun-exposed skin (lower leg). These tissue types had 5491 and 8567 eQTLs reported by GTEx, respectively, based on FDR < 0.05. After combining these two lists, excluding redundant eSNPs, and restricting to SNP with a MAF > 5% in our population, we were left with 9952 SNPs that were eSNPs in skin tissue. Restricting to these SNPs, we conducted SNP-arsenic interaction analyses in relation to incident skin lesions. We modeled urinary arsenic as a continuous exposure (log-transformed), and ordinal variable based on quartiles, as well as a binary variable defined by the median value.
Results
SNP × arsenic interaction for arsenic-associated CpG sites (Step 1)
Based on our prior epigenome-wide association study (EWAS) of arsenic exposure and DNA methylation (Argos et al. 2015) , we selected four CpG sites associated with urinary arsenic with Bonferroni significance (p < 1 × 10 −7 ) ( Table 2 ). In genome-wide searches for SNPs showing evidence of interaction with arsenic in relation to these four phenotypes, we identified one region (on chromosome 11) showing modest evidence of SNP-arsenic interaction. SNPs in this region (lead SNP 11:43330815) showed evidence of interaction with arsenic in relation to cg01225779, a CpG on chromosome 5 (Fig. 2) . For these analyses, arsenic was treated as dummy variable with a cut point at the median, due to inflation in the G×E test statistics observed when arsenic was treated as a continuous variable.
SNP × arsenic interaction for arsenic-associated DNA methylation patterns (Step 1)
Following PCA of these four arsenic-associated CpG sites, we observed that the first PC (PC 1) was strongly associated with arsenic exposure (r = 0.45; p < 0.0001) (Fig. 3) . Using this PC as a proxy for "epigenetic response to arsenic," our genome-wide search for SNPs that modify the association of arsenic with this "epigenetic response" variable did not identify any SNPs with clear main effects or G×E effects on the constructed PC (Fig. 4) .
SNP × arsenic interaction analysis for arsenic-associated transcripts (Step 1)
Based on a genome-wide search for association between urinary arsenic and gene expression levels, we selected 4056 arsenic-associated genes (FDR = 0.05). Following PCA of Fig. 2 Genome-wide SNP × arsenic analyses for four arsenic-responsive CpG probes these arsenic-associated genes, we identified 45 arsenicassociated PCs that we then used as proxies for "transcriptome response to arsenic." We searched the genome for SNPs that modified the association between urinary arsenic and these PCs, and only three of the PCs showed a p value < 5 × 10 −8 (Fig. 5) . The lead SNPs best representing these signals were rs17060130 on chromosome 6 and rs12105595 on chromosome 2.
SNP × arsenic interaction for cis-meQTLs and cis-eQTLs (Step 1)
Among the 7643 cis-eQTLs identified in this dataset, we tested G×E to determine if arsenic modified the association between the lead eSNP and its associated transcript. Among these eQTLs, three eSNPs showed p values surpassing Bonferroni correction (Fig. 6) . Among the 84,853 cis-meQTLs identified in this dataset, none showed strong evidence of Fig. 3 The distribution of the PC representing epigenomic response to arsenic, stratified by arsenic octiles (Fig. 6 ). This null result included the arsenic-associated CpGs, of which three of the four had a meQTL (cg06121226 and two others).
Step 2: Testing identified SNPs for interaction with arsenic in relation to skin lesion status Despite the fact that none of our analyses in step 1 provided strong evidence for any specific SNP, we selected the six SNPs showing modest evidence of association based on step 1 analyses. We then tested each SNP for SNP-arsenic interaction in relation to skin lesion case/controls status and for marginal association with skin lesions status. In the analyses of interaction (Table 3) , none of the SNPs showed a nominally significant p value of interaction (p < 0.05). This was true in both models with exposure modeled as a continuous variable (log-transformed urinary arsenic) and an ordinal variable (urinary arsenic quartiles). Similarly, in analyses of SNPs' marginal association with skin lesion status, no SNP showed evidence of association.
G×E analysis of SNPs that are eQTLs in skin
We tested SNP-arsenic interaction in relation to incident skin lesions for 9952 SNPs that are eQTLs in skin tissue based on results from GTEx. However, none of these analyses identified SNPs showing a striking interaction with exposure (Fig. 7) . When we analyzed all SNPs in the genome for evidence of SNP-arsenic interaction in relation to skin lesion status, we observe a suggestive signal on chromosome 1, with the lead SNP being an intergenic SNP residing between the SNX7 gene and the LPPR5 gene (Fig. 8) . SNX7 is involved in intracellular trafficking, but its exact function is unknown. LPPR5 is involved in converting phosphatidic acid to diacylglycerol, glycerolipid synthesis, and receptor-activated signal transduction mediated by phospholipase D. Lead SNP rs6659080 is reported as an eQTL in only two tissues (according to GTEx); it is associated with LPPR5 expression in testicular tissue and SNX7 expression in aorta. However, it should be noted that rs6659080 is in strong LD with dozens of nearby SNPs (Fig. 8 ).
Discussion
In this paper, we described a two-step omic approach that addresses the limitations of standard genome-wide interaction approaches. Using existing genome-wide SNP data from a large Bangladeshi cohort study specifically designed to assess the effect of arsenic exposure on health, we searched for gene-arsenic interactions by first conducting a genome-wide search for SNPs that modify the effect of arsenic on molecular phenotypes (gene expression and DNA methylation features). Then, using this set of SNPs that interact with arsenic in relation to molecular phenotypes, we tested SNP-arsenic interactions in relation to skin lesion status, a hallmark characteristic of chronic arsenic toxicity. This approach leverages high-quality measures of arsenic exposure and restricts analyses to SNPs with enhanced probability of interaction with arsenic (by leveraging existing gene expression and DNA methylation data) to overcome the limitations of standard statistical genome-wide interaction approaches. Evidence has suggested that arsenic exposure itself fails to fully explain the presence of arsenical skin lesions in an exposed population and that inter-individual variation may play an important role in determining sub-populations at higher risk of developing the disease at similarly exposed levels (Concha et al. 2002) . Epidemiologic studies have shown interaction with sex, age, body mass index (Ahsan et al. 2006) , smoking (Chen et al. 2006) , socioeconomic status (Argos et al. 2007 ), nutritional status (Zablotska et al. 2008) , and genetic variants [as reviewed in (Ghosh et al. 2008; Hernandez and Marcos 2008) ]. There is known interindividual variability in the methylation capacity of arsenic [as reviewed in (Tseng 2009)] , which has been hypothesized to partly explain the variability in susceptibility to arsenic toxicity and may be attributed in part to genetic variation in genes known to metabolize arsenic. Thus, individuals who do not fully methylate arsenic efficiently could potentially be at increased risk of arsenic-related health effects due to this gene-environment interaction.
G×E interactions are believed to influence complex diseases, but detecting G×E has proven difficult. The genome-wide association approach has been successful for identifying new susceptibility variants for a wide array of diseases (Visscher et al. 2012) . However, variants identified in genome-wide association studies typically do not show strong evidence of interaction with environmental risk factors (Campa et al. 2011; Hutter et al. 2012 Hutter et al. , 2010 Milne et al. 2010; Nickels et al. 2013; Travis et al. 2010) . Explicit searches for G×E (as opposed to detection based on marginal effects) may be required to detect interacting variants (Hutter et al. 2013) . Limited progress has been made identifying G×E interactions in the epidemiological setting using existing statistical methods for genome-wide searches for interaction. The genome-wide interaction approach suffers from several key limitations, including (1) very large sample size requirements due to the conduct of many statistical tests of interaction and (2) a lack of high-quality exposure data in studies with large-scale genomic data. Considering these limitations, most genome-wide interaction studies that rely on statistical evidence of interaction alone are likely to be underpowered to detect G×E interactions.
New approaches for G×E detection are needed that leverage high-quality exposure measures ). Genome-wide interaction studies are typically conducted in the context of large genome-wide association consortia studies (Austin et al. 2012 ) not designed to assess the impact of specific environmental factors. Thus, exposure measures are often questionnaire-based and/or retrospective, resulting in measurement error that reduces power for genome-wide interaction analyses. Using high-quality, accurate measures of environmental factors with established impact on disease in well-characterized populations will enhance power for G×E detection (Hutter et al. 2013) .
Focusing G×E studies on variants that influence molecular, omics phenotypes through G×E can potentially enhance power for G×E detection. Power for genome-wide interaction studies is limited because large numbers of tests are conducted. Focusing analyses on a smaller set of variants with an increased likelihood of G×E can increase power. In cases where transcriptomic or other omics data are available for individuals with exposure data, one could conduct a screen for variants that modify the effect of exposure on these molecular phenotypes. In other words, variants that interact with exposure to influence disease should also influence the cellular/molecular response to exposure.
We believe that there is great promise in shifting the focus of G×E interaction research from agnostic genome-wide interaction testing to understanding how genetic variants influence humans' response to an exposure at the molecular level. Our approach leverages omics data (gene expression and DNA methylation) to first test for gene-arsenic interactions in relation to intermediate molecular phenotypes, with evidence suggesting they represent the underlying mechanistic pathways between chronic arsenic exposure and skin lesion outcome. The major strength to first evaluating interactions with intermediate molecular phenotypes is that power may be enhanced to observe stronger interaction effects for the intermediate phenotype since it is more proximal to exposure than the disease outcome. Additionally, the environmental measure may better reflect the relevant exposure window for the intermediate phenotype as compared to disease outcomes with a longer latency period, also increasing ability to observe G×E interactions. However, the objective of this paper was not to conduct a direct evaluation of our approach in comparison with other gene-environment approaches; therefore, additional methodologic evaluations are needed to formally compare various statistical approaches.
We acknowledge several limitations of our study. While altered gene expression and DNA methylation are associated with our exposure and outcome of interest, there are other pathways that underlie the association between chronic arsenic exposure and skin lesion status. Therefore, the molecular phenotypes evaluated do not represent the only arsenic toxicity pathways. The inclusion of additional intermediate molecular phenotypes (i.e., proteome, microbiome, epigenome) may more comprehensively characterize mechanistic pathways and improve the first-step selection of promising interaction SNPs based on our approach. While previous research has demonstrated significant roles of SNPs on gene expression (eQTL) and DNA methylation (meQTL) as well as arsenic exposure on each of these molecular phenotypes, it is possible that SNPs and arsenic do not interact with respect to these molecular phenotypes. Gene-arsenic interactions may be more apparent for other molecular phenotypes. Also, our study was limited to omics phenotypes measured in blood, while some disease-relevant G×E may be detectable in multiple tissues, the ideal tissue types for detection of G×E will likely be the disease-relevant tissues (e.g., skin). We attempted to address this limitation by searching for G×E among SNPs known to be eQTLs in skin tissue, although no clear interactions were identified.
We evaluated genome-wide SNP-arsenic interactions in step 1 only for those molecular traits (differentially methylated CpGs or transcripts) with evidence of marginal/independent association with arsenic exposure. We also evaluate SNP-arsenic interactions in step 1 for SNPs identified from eQTL and meQTL analyses with evidence of marginal/independent association with SNPs. This strategy was employed to reduce the number of multiple comparisons, but is based on the assumption that a marginal effect with either the exposure or gene must be observed for there to be an interaction effect. This assumption may not hold for some G×E interactions.
With the emergence of additional omics data in the epidemiologic setting, our approach may have the potential to boost power for genome-wide interaction research, enabling the identification of interactions that will enhance our understanding of disease etiology and our ability to develop interventions targeted at susceptible sub-populations.
